NCT02089932

Dexmedetomidine in Different Dose Levels as Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block.

The Effects of Different Dose Levels of Peri-neural Dexmedetomidine on the Pharmacodynamic and Side Effects Profiles of Bupivacaine-induced Ultrasound-guided Femoral Nerve Block

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Cairo University · Academic / Other
• Sex: All
• Age: 15 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

The duration of sensory block after single dose of long acting local anesthetics is not sufficient to avoid the postoperative use of opioids. Alpha-2 adrenoceptor agonists such as clonidine have been shown to increase the duration of peripheral nerve block. Dexmedetomidine is a more potent and selective α-2-adrenoceptor compared to clonidine. To the best of our knowledge, the use of Dexmedetomidine in different dose levels as adjuvant to local anesthetic was not previously reported for femoral nerve block.

Conditions

• Dexmedetomidine
• Femoral Nerve Block
• Arthroscopic Knee Surgery

Interventions

Type	Name	Description
DRUG	peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block	ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally. After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia.
DRUG	Placebo

Timeline

• Start date: 2014-02-01
• Primary completion: 2015-04-01
• Completion: 2015-06-01
• First posted: 2014-03-18
• Last updated: 2019-01-15

Locations

1 site across 1 country: Egypt